Armistice Capital’s Co-Diagnostics CODX Stock Holding History

Armistice Capital’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$732K	Buy	+236,000	New	+$726K	0.01%	198

Other funds holding CODX

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAG

Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital's CODX Position: Q2 2026 in Review

Armistice Capital opened a new position in Co-Diagnostics (CODX) in Q2 2026: 236,000 shares worth $732K. The stake represents 0.01% of the portfolio and ranks #198 among its holdings.

24 funds tracked by Wall St. Rank hold CODX as of Q2 2026.

Armistice Capital held 236,000 shares of Co-Diagnostics worth $732K as of Q2 2026.
Co-Diagnostics was a new Armistice Capital position in Q2 2026.
Co-Diagnostics made up 0.01% of Armistice Capital's portfolio in Q2 2026, its #198 holding.
24 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.